

**Publication alert:**


**Heterogeneity within and between physician-diagnosed asthma and/or COPD: NOVELTY cohort**

Helen K Reddel, Jørgen Vestbo, Alvar Agustí, Gary P Anderson, Aruna T Bansal, Richard Beasley, Elisabeth H Bel, Christer Janson, Barry Make, Ian D Pavord, David Price, Eleni Rapsomaniki, Niklas Karlsson, Donna K Finch, Javier Nuevo, Alex de Giorgio-Miller, Marianna Alacqua, Rod Hughes, Hana Müllerová and Maria Gerhardsson de Verdier, for the NOVELTY study investigators

Eur Respir J 2021;58(3):2003927

Studies typically focus on asthma and COPD separately, limiting understanding of disease mechanisms and treatment options

NOVELTY is a first-of-a-kind study of 11,243 patients with asthma, COPD or both diagnoses in 18 countries\*




**Objectives**

Investigate similarities and differences between patients diagnosed with asthma and/or COPD of varying levels of severity

Describe baseline clinical, physiological and biomarker characteristics of the global NOVELTY population

**Baseline demographics (N=11,243)**




\*>90% of patients had complete data for demographics

Diagnosis and severity were based on physician assessment, with no diagnostic criteria specified



Patients from primary care: **46.7%**

Differences within and overlap between patients in the asthma, asthma+COPD and COPD groups were observed for:




Clinical characteristics associated with poor outcomes such as low lung function and exacerbations increased with greater physician-assessed severity, but were still present among patients with mild disease



There is substantial heterogeneity within, and overlap between, the different physician-assigned diagnosis and severity groups

Treatment strategies for patients with obstructive lung disease should be targeted towards their individual characteristics and disease traits rather than their diagnostic label to improve outcomes

Disease severity in asthma and/or COPD is better measured through the experiences of the patient than their physician-assigned disease label or severity category



\*Data for patients from China were excluded from the present analyses due to a change in regulations about data transfer in May 2019. COPD, chronic obstructive pulmonary disease; NOVELTY, NOVEL observational longitudinal study.

**Reference**

Reddel HK, et al. Heterogeneity within and between physician-diagnosed asthma and/or COPD: NOVELTY cohort. Eur Respir J 2021;58(3):2003927.